Bank of America Cuts Immunovant (NASDAQ:IMVT) Price Target to $45.00
Bank of America reduced their target price on Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday.
Source link
Similar Posts
Here Are My Top 2 TSX Stocks to Buy Right Now
Image source: Getty Images The Canadian equity market continues to perform well, with investors banking on higher-than-expected growth moving forward as interest rates fall. Indeed, it’s been a very interesting period of time that’s benefited investors, with most major stock indices reaching new all-time highs. Of course, there are many who suggest these good times…
CMM – Capricorn Metals Limited
Huge volume and a 31.50% share price increase to 11.7c today after CMM announced a total equity raising of up to $18.26 million through the issue of up to 280,922,429 new shares at an issue price of 6.5c per share to advance development at the Karlawinda Gold Project. The equity raising of $15 million will…
MOIL: 400 Paar
Source: Earnings Call of MOIL Ltd Source link
Wall Street Week Ahead
Wall Street’s focus next week will be squarely on April 2 – a date U.S. President Donald Trump has dubbed “Liberation Day.” He is expected to implement reciprocal tariffs, along with a 25% tariff on automobile imports announced last week. Turmoil caused by his trade war escalation has roiled markets, and stocks could be in…
